Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to Strong-Buy at Zacks Research

Key Points

• Zacks Research upgraded Regeneron Pharmaceuticals from “hold” to “strong buy.” The broader analyst consensus is “Moderate Buy,” with a consensus price target of $802.18.
• Regeneron’s latest quarterly results exceeded expectations, with EPS of $14.29 versus a $10.16 consensus estimate and revenue of $4.29 billion versus $3.82 billion expected. Revenue increased 16.7% year over year.
• The stock opened at $750.51, while investors face potential competitive pressure to Eylea from Kodiak Sciences’ positive Phase 3 eye-treatment results; insiders have also sold $3.43 million of shares over the past 90 days.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) was upgraded by equities research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a report released on Monday, Zacks reports.

A number of other brokerages have also recently commented on REGN. Citigroup increased their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a "neutral" rating in a report on Monday, August 3rd. HSBC increased their price target on shares of Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a "buy" rating in a research note on Thursday, September 10th. Truist Financial raised their price objective on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a research note on Friday, July 31st. Weiss Ratings restated a "hold (c)" rating on shares of Regeneron Pharmaceuticals in a report on Monday, September 21st. Finally, Cantor Fitzgerald raised their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $802.18.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $750.51 on Monday. The company has a market cap of $77.27 billion, a price-to-earnings ratio of 18.55, a PEG ratio of 1.47 and a beta of 0.20. Regeneron Pharmaceuticals has a 1 year low of $541.00 and a 1 year high of $859.34. The stock's 50 day simple moving average is $782.91 and its two-hundred day simple moving average is $720.82. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, beating the consensus estimate of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.Regeneron Pharmaceuticals's quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $12.81 EPS. As a group, equities analysts anticipate that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur Ryan sold 200 shares of the company's stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares of the company's stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the business's stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the sale, the director directly owned 1,703 shares of the company's stock, valued at approximately $1,362,400. This trade represents a 31.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 4,146 shares of company stock worth $3,432,488 over the last 90 days. Corporate insiders own 6.97% of the company's stock.

Institutional Trading of Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. SHP Wealth Management bought a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $26,000. Western Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals in the fourth quarter worth $29,000. Mowery & Schoenfeld Wealth Management LLC bought a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $29,000. Finally, Trust Co. of Vermont purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. Institutional investors own 83.31% of the company's stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Sell-side analysts collectively rate Regeneron a “Moderate Buy,” indicating that the broader analyst consensus remains favorable. Regeneron also compares attractively on valuation against some biotechnology peers. Regeneron Pharmaceuticals Stock Rated Moderate Buy by Sell-Side Analysts
• Positive Sentiment: Biohaven has begun enrolling patients in a combination study pairing its investigational cancer therapy BHV-1530 with Regeneron’s Libtayo. The agreement could support additional development opportunities for Libtayo, though the program remains early stage. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron is expected to report third-quarter results on October 30. The upcoming earnings release may provide updates on Eylea demand, guidance and the company’s broader pipeline, making it a near-term catalyst. Should You Buy Regeneron Pharmaceuticals Stock Before October 30?
• Negative Sentiment: Kodiak Sciences reported positive Phase 3 DAYBREAK results for two potential wet age-related macular degeneration treatments. The candidates met primary endpoints versus Eylea and may offer dosing approximately every six months, compared with Eylea’s current roughly eight-week schedule. The data raise the prospect of longer-term competitive pressure on Regeneron’s key eye-care franchise and prompted a sharp rally in Kodiak shares. Kodiak Skyrockets on Positive Study Data for Two Eye Drugs
• Negative Sentiment: Royal Bank of Canada reaffirmed its “Sector Perform” rating and set a $737 price target, below the referenced share price, signaling limited near-term upside in that analyst’s view. Regeneron Sector Perform Rating Reaffirmed by RBC

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.